Introduction 1
The microtubule-associated protein tau (MAPT) is involved in the 2 pathogenesis of several forms of dementia, including Alzheimer's disease 3 (AD) and frontotemporal dementia (FTD) . Mutations in the MAPT gene are 4 causal for some familial forms of FTD (Ghetti et al., 2015) , and the formation 5 of intracellular, hyperphoshorylated aggregates of tau (neurofibrillary tangles, 6 NFTs) is a common pathological feature in AD, FTD and other dementias 7 (Grundke- Iqbal et al., 1986; Kosik et al., 1986) . Disease progression, and 8 clinical severity of symptoms, is associated with a predictable spatial and 9 temporal order of appearance of NFTs in different forebrain regions (Braak 10 and Braak, 1991) . This has led to the proposal that these diseases actively 11 spread from diseased to healthy neurons in a spatial and temporal We used human stem cell-derived neurons to address open questions about 1 the efficiency with which tau enters human neurons, which forms (monomeric 2 and aggregated) of tau enter neurons, and the routes by which they do so. 3
We find that both forms of tau are efficiently taken up by human neurons, by 4 overlapping but distinct mechanisms, consistent with regulated endocytosis. 5
Monomeric tau enters neurons by two different routes and is actively trafficked 6 within the neuron. Tau entry into neurons can be slowed by antibody binding, 7 however, extracellular tau-antibody complexes are internalised into 8 intracellular compartments. 9
RESULTS 1 2
Rapid and efficient entry of extracellular monomeric and aggregated tau 3 into human neurons 4
We first analysed the ability of monomeric or aggregated tau (P301S) protein 5 to enter human cortical neurons from the extracellular milieu. We used the tau 6 P301S variant, an autosomal dominant mutation that causes early onset FTD 7 with high penetrance (Bugiani et al., 1999; Guo et al., 2017) , enabling us to 8 study the transmission of a disease-relevant variant that differs from normal 9 tau by a single amino acid. To do so, purified recombinant monomeric (native) 10 or heparin-aggregated tau protein conjugated to an amide reactive 11 fluorophore (tau-Dylight 488 NHS ester) were incubated with iPSC-cell 12 derived neurons for 2 hours. After extensive washing, monomeric and 13 aggregated tau-Dylight were both detected in cells expressing the neuron-14 specific microtubule-associated protein MAP2, confirming that both forms of 15 tau enter neurons ( Figure 1A ). Tau-Dylight was found predominantly within 16 the somatic compartment of neurons ( Figure 1A ). After four hours incubation 17 with extracellular tau, flow cytometry analysis ( Figure 1B ,C) revealed that 83% 18 and 73% of dissociated cells contained monomeric or aggregated tau-Dylight, 19 respectively, demonstrating that extracellular tau efficiently enters human 20 neurons in culture. 21 22
Concentration-dependent entry of tau into neurons via low pH transport 23 vesicles 24
Live imaging of human cortical neurons was used to investigate the 25 underlying mechanisms of neuronal entry of monomeric and aggregated tau. 26
To do so, we prepared purified recombinant tau P301S protein conjugated to 27 a maleimide reactive pH-sensitive dye (tau-pHrodo Red maleimide), a 28 reporter detectable in low pH environments, including late endosomes and 29 lysosomes. Incubation of tau-pHrodo with human neurons at a range of 30 concentrations from 2.5 to 25 nM (0.12 to 1.2µg.ml -1 , diluted in culture 31 medium) showed that tau entry to neurons is rapid and concentration 32 dependent, as visualised by live imaging. Intraneuronal fluorescent punctae 1 were observed within the first ten minutes of exposure to monomeric tau-2 pHrodo ( Internalisation of aggregated tau-pHrodo ( Figure 2D ) was also found to be 11 concentration dependent ( Figure 2E ). However, unlike monomeric tau-12 pHrodo, the number of detectable tau-pHrodo positive objects ( Figure 2F ) did 13 not increase immediately, but displayed a lag for the first hour ( Figure 2E ). Monomeric and aggregated tau appear in early endosomes and in 23 lysosomes 24
To establish the route of vesicular internalisation of monomeric and 25 aggregated tau, we analysed the appearance of tau-Dylight in endosomal or 26 lysosomal compartments in iPSC-derived human neurons. Monomeric or 27 aggregated tau-Dylight (total protein concentration 10μg.ml -1 ; ~250nM) was 28 incubated with neurons for up to 6 hours, then extensively washed to remove 29 extracellular protein and fixed. Co-localisation of tau with endosomes, defined 30 by early endosomal antigen-1 (EEA1) immunofluorescence ( Figure 3A ), or 31 late endosomes and lysosomes, defined by LAMP1 immunofluorescence 1 ( Figure 3B ), was analysed by confocal microscopy. 2 3
In agreement with the monomeric tau-pHrodo experiments, monomeric tau-4
Dylight is rapidly taken up into neurons ( Figure 3C ). In contrast, IgG-Dylight 5
shows little detectable entry into neurons throughout the time course (data not 6 shown). As early as 1 hour after addition of extracellular tau, monomeric and 7 aggregated tau-Dylight were co-localised in EEA1 early endosomes. 8
Monomeric and aggregated tau-Dylight were also detected in LAMP1 late 9 endosomes and lysosomes, consistent with endocytosed proteins first 10 reaching the early endosomes, before endosomes mature to become late 11 endosomes. 12
13
Live imaging ( Figure 3G , Supplementary Movie 2) of neurons incubated with 14 aggregated tau-pHrodo (four hours; 0.7µg.ml -1 ) enabled the longer-term 15 tracking of tau-pHrodo-containing vesicles within neurons. Tau-containing 16 vesicles were dynamically and rapidly (>10µm/second) transported in both 17 antero-and retrograde directions along neurites, and could rapidly reverse 18 direction of transport ( Figure 3G ). Thus, monomeric and aggregated tau both 19 efficiently enter neurons via the endosome-lysosome system, and are actively 20 trafficked within vesicles over long distances within neurons over several 21
hours. 22 23

Differential effects of dynamin inhibition on endocytosis of monomeric 24 and aggregated tau 25
As extracellular monomeric and aggregated tau utilise endosomal pathways 26 to enter neurons, but display different kinetics of uptake, we examined 27 whether the underlying internalisation mechanisms of tau protein species 28
differ. First, we tested the sensitively of monomeric and aggregated tau 29 internalisation to the small molecule inhibitor Dynasore (Figure 4) , an inhibitor 30 of the GTPase Dynamin, which is required for numerous membrane fission The amount of monomeric tau entering neurons, as measured by total 5 fluorescent intensity of intracellular monomeric tau-pHrodo vesicles, is 6 significantly reduced by dynamin inhibition, as shown at 1 and 3 hours after 7 addition of extracellular tau ( Figure 4B ). This is also reflected in the significant 8 reduction in the number of tau-pHrodo positive objects at 1 hour (compared 9 with vehicle control; Figure 4C ). The kinetics of appearance of intracellular 10 monomeric tau-pHrodo objects changes in the presence of dynamin inhibitor, 11
displaying an initial lag in entry. However, the number of tau-pHrodo objects 12 then reaches the same level as vehicle-treated controls by 3 hours, although 13 not the same total intensity ( Figure 4C ), which may reflect a reduction in 14 endosome/lysosome acidification in the presence of Dynasore. This suggests 15 that there are two distinct mechanisms of entry of monomeric tau into human 16 neurons, one of which is rapid and dynamin-dependent, and the other slower 17 and independent of dynamin. 18
19
The effect of dynamin inhibition on entry of aggregated tau is more 20 pronounced than on monomeric tau ( Figure 4D -F). The total fluorescent 21 intensity of intracellular aggregated tau-pHrodo is consistently reduced by 22 more than 70% at 1 and 3 hours after tau addition ( Figure 4E ), and the 23 number of tau-pHrodo positive objects is reduced by 95% ( Figure 4F ). These 24 data indicate that, at the concentrations studied, that aggregated tau enters 25 neurons almost entirely via clathrin-mediated endocytosis. as reflected in the 95% reduction in the number of monomeric tau-pHrodo 10 positive objects after three hours incubation in the presence of 1µM 11
Cytochalasin D ( Figure 5C ). In contrast, disruption of actin polymerisation with 12
Cytochalasin D had little effect on entry of aggregated tau (total fluorescent 13 intensity and number of objects; Figure 4D -F). 14
15
Live imaging of tau entry with pHrodo-tau may not detect intracellular pools of 16 tau that enter via a different mechanism, avoiding low-pH environments. 17
Additionally the pharmacological treatments may also effect the acidification 18 of intracellular vesicles, which could affect the pHrodo signal. To control for 19 this, we performed tau-Dylight internalisation assays in the presence of 20 100µM Dynasore or 1µM Cytochalasin D (Supplementary Figure 2) , with three 21 hours of incubation with 100µM extracellular monomeric or aggregated tau. 22
Compared with the live imaging studies, relatively high concentrations of 23 aggregated tau were used to investigate whether the dynamin-dependence 24 and actin-independence of neuronal entry seen by live imaging were related 25 to the lower molarity of aggregated versus monomeric tau used for those 26 experiments. These independent assays confirmed the same differential 27 effects of the two inhibitors observed by live imaging of pHrodo-tau: at the 28 three hour assay point, dynamin inhibition had no effect on the number of 29 
Anti-tau antibodies slow neuronal internalisation of extracellular tau 1
It is not currently known if tau entry into neurons requires specific domains of 2 tau, specific cell surface binding proteins or receptors. Antibodies that 3 recognise extracellular tau are a potential therapeutic strategy for slowing 4 disease progression through the CNS by inhibiting tau entry into neurons 5 3). The kinetics of monomeric tau entry are affected by the presence of tau-22 specific antibodies, such that an initial lag in the appearance of defined tau-23 pHrodo-positive objects was observed ( Figure 6B ). 24
25
Tau antibodies also reduce entry of aggregated tau uptake into human 26 neurons ( Figure 6C ). In the presence of anti-tau pAb the number of aggregated 27 tau-pHrodo vesicles was reduced by more than half ( Figure 6D ; 28 Supplementary Figure 3 ). IgG antibodies that do not recognise tau appear to 29 have some minor effects on monomeric and aggregated tau entry, which may 30 be due to competition between tau and IgG for bulk endocytosis. 31
The effect of tau antibodies on the entry of monomeric tau-Dylight into 1 neurons was also tested ( Supplementary Figure 3 ), using the same 2 concentrations and pre-incubation time as the tau-pHrodo assays. After three 3 hours of incubation with antibodies and extracellular monomeric or 4 aggregated tau, neurons were washed, fixed and number of intracellular tau-5
Dylight punctae were quantified. These independent assays confirm that tau-6 specific antibodies significantly reduce the amount of tau-Dylight entering 7 neurons (Supplementary Figure 3) . 8 9
Entry of aggregated tau-antibody complexes into neurons 10
Although tau was pre-incubated with a large molar excess of antibodies (10x) 11 before addition to neurons, a notable amount of both monomeric and 12 aggregated tau still entered neurons. This raised the question whether the tau 13 that entered neurons under these conditions did so in a complex with 14 antibodies, or that a fraction of antibody-free tau was available for neuronal 15 entry. To distinguish between these possibilities, we performed additional 16 assays using pre-formed aggregated tau-Dylight-antibody complexes. After 17 three hours of incubation, antibodies were detected in the fixed neurons with a 18 secondary antibody specific to the host species (anti-rabbit polyclonal; Figure  19 7) and also imaged for tau-Dylight. Intraneuronal punctae positive for both 20 tau-Dylight and tau specific antibodies were detected after binding of 21 extracellular tau with anti-tau pAb , demonstrating that tau-antibody complexes 22 do enter human neurons. No intraneuronal tau-antibody complexes were 23 detected when aggregated tau was incubated with IgG control. 24 25 26
Discussion 1
We find here that both monomeric and aggregated tau (P301S) efficiently 2 enter human neurons, arguing that tau entry to neurons is a constitutive 3 biological process, and not a disease-specific phenomenon. Both species of 4 tau enter neurons via a dynamin-dependent process, with monomeric tau also 5 entering neurons through a second, slower pathway dependent on actin 6 polymerisation. Monomeric and aggregated tau access neurons via the 7 lysosome/endosome system, and a fraction of tau is dynamically transported 8 long distances in neurons within low pH vesicles for lengthy periods. The 9 amount of monomeric and aggregated tau entering neurons is reduced by 10 polyclonal anti-tau antibodies. However, a notable amount of tau enters 11 neurons complexed with antibodies, even in the presence of a ten-fold molar efficiently and rapidly enters healthy human neurons, and does so as 21 efficiently as aggregated tau. We find that there are two mechanisms of entry 22 of monomeric tau to neurons: a rapid early phase that can be blocked by 23 dynamin inhibition, and a second, slower phase that it does so in an actin-24 dependent manner. These two mechanisms suggest that monomeric tau 25 enters neurons via a rapid saturable clathrin-mediated endocytic mechanism 26 and also by bulk endocytosis (Loebrich, 2014) . In contrast to monomeric tau, 27 aggregated tau entry is independent of actin polymerisation and largely 28 and that receptor shows specificity for aggregated synuclein over the 6 monomeric form, arguing that although both species of tau enter neurons via 7 clathrin-mediated endocytosis, they may do so through distinct surface 8 receptors. As a largely disordered protein, the most obvious candidate region 9
for recognition for cellular entry of monomeric tau is the highly ordered 10 microtubule-binding region of tau (Butner and Kirschner, 1991) . Detailed 11 understanding of the different paths of entry for monomeric and aggregated 12 tau will be useful for investigating the potential for specifically preventing inter-13 neuronal transfer of aggregated tau without interfering with transfer of non-14 pathogenic forms. 
Labelled tau internalization assays 24
Tau P301S labelled with either Dylight or pHrodo was diluted in neuronal 25 maintenance medium tissue culture medium and added to neurons at the 26 concentration and for the time indicated. Neurons were either washed three 27 times using 1xHBSS before processing for immunofluorescence, processing 28 for flow cytometry or subjected to live imaging. 29 1
Immunostaining, confocal microscopy and data analysis 2
Immunohistochemistry was performed on neurons as previously described 3 (Shi et al., 2012) using the following primary antibodies: MAP2 from Abcam 4 (ab5392); EEA1 and LAMP1 from Cell Signaling (C45B10 and D2D11). 5
Secondary antibodies used were goat anti mouse Alexa594 (A21125), goat 6 anti chicken Alexa 647 (A21449), goat anti rabbit Alexa 546 (A11010), donkey 7 anti mouse Alexa 594 (A21203), donkey anti rabbit Alexa 594 (A21207, all 8 from Thermo Fisher). Images were acquired using Olympus FV1000 or Opera 9
Phenix. Typically conditions were repeated in triplicate and >12 images were 
